Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1983)
  2. Solid Tumor Oncology Division (1615)
  3. GSK Faculty (761)
  4. Survivorship Research (635)
  5. Population Sciences Research Program (612)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (412)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2093)
  2. Meeting Abstract (2072)
  3. Book Section (179)
  4. Review (88)
  5. Editorial (80)
  6. Guidelines (35)
  7. Correspondence (24)
  8. Book Whole (17)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1983)
  2. Solid Tumor Oncology Division (1615)
  3. GSK Faculty (761)
  4. Survivorship Research (635)
  5. Population Sciences Research Program (612)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (65)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1666)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment and outcomes of frail patients with newly diagnosed high-grade gliomas: Should we consider changing our treatment approach?
    Meeting Abstract

    Sielski, N.; Reiner, A.; Schaff, L.; Imber, B.; Pike, L.; Carver, A.; Pentsova, E.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Integration of functional magnetic resonance imaging into stereotactic radiosurgery planning to reduce symptomatic radiation necrosis
    Meeting Abstract

    Gui, C.; Jenabi, M.; Daly, J.; Gillick, C.; Bradley, T.; Sze, E.; Maldonado, R.; Tiwari, A.; Stember, J.; Mankuzhy, N.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Long term follow-up of resection plus cesium-131 brachytherapy for previously irradiated recurrent brain metastases
    Meeting Abstract

    Yacoub, I.; Young, R. J.; Reiner, A. S.; Gantini-Larsen, A.; Yamada, Y.; Pike, L. R. G.; Krebs, S.; Damato, A.; Aramburu-Nunez, D.; Yu, K. K. H.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high-grade glioma
    Meeting Abstract

    Miller, A. M.; Nandakumar, S.; Holle, B. M.; Kreitzer, C.; Song, T.; Tartaro, M.; Hertz, C. A. J.; Rafailov, J.; Campos, C.; Brannon, A. R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A metabolic biomarker in glioblastoma: A promising application of co-polarized [1-(13)C]pyruvate and [1-(13)C]dehydroascorbate
    Meeting Abstract

    Coffee, E.; Porcari, P.; Kim, N.; Patel, S.; Berishaj, M.; Deh, K.; Rahimi-Keshari, K.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Real-world experience with circulating tumor DNA in cerebrospinal fluid in patients with central nervous system tumors
    Meeting Abstract

    Hickman, R.; Miller, A. M.; Holle, B. M.; Jee, J.; Liu, S. Y.; Ross, D.; Yu, H.; Riely, G. J.; Ombres, C.; Gerwitz, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Development of a 3D organotypic explant platform to study oncolytic virus treatment response in glioblastoma
    Meeting Abstract

    Abou-Mrad, Z.; Yu, K.; Tabar, V.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
    Meeting Abstract

    Doi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
    Meeting Abstract

    Ohe, Y.; Subbiah, V.; Sukrithan, V.; Robinson, B.; Deschler-Baier, B.; Iwasa, T.; Ohashi, K.; Goto, K.; Nishio, M.; Satouchi, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2 - metastatic breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save